Zollinger-Ellison syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
Line 23: | Line 23: | ||
*[[Hormonal therapy]] | *[[Hormonal therapy]] | ||
:*[[Octreotide]] can be used to slow down acid secretion. Somatostatin analogue octreotide is effective in controlling systemic effects related to multiple liver metastases from a gastrinoma. <ref name="pmid14564638">{{cite journal| author=Saijo F, Naito H, Funayama Y, Fukushima K, Shibata C, Hashimoto A et al.| title=Octreotide in control of multiple liver metastases from gastrinoma. | journal=J Gastroenterol | year= 2003 | volume= 38 | issue= 9 | pages= 905-8 | pmid=14564638 | doi=10.1007/s00535-002-1170-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14564638 }} </ref> | :*[[Octreotide]] can be used to slow down acid secretion. Somatostatin analogue octreotide is effective in controlling systemic effects related to multiple liver metastases from a gastrinoma. <ref name="pmid14564638">{{cite journal| author=Saijo F, Naito H, Funayama Y, Fukushima K, Shibata C, Hashimoto A et al.| title=Octreotide in control of multiple liver metastases from gastrinoma. | journal=J Gastroenterol | year= 2003 | volume= 38 | issue= 9 | pages= 905-8 | pmid=14564638 | doi=10.1007/s00535-002-1170-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14564638 }} </ref> | ||
:* Octreotide is a safe and effective adjunct to surgical strategies for the management of GEP neoplasia in hypergastrinemic MEN-1 patients. <ref name="pmid10570446">{{cite journal| author=Burgess JR, Greenaway TM, Parameswaran V, Shepherd JJ| title=Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis. | journal=Cancer | year= 1999 | volume= 86 | issue= 10 | pages= 2154-9 | pmid=10570446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10570446 }} </ref> | |||
:*Octreotide is an effective antitumor treatment in patients with progressive malignant gastrinoma. Octreotide treatment helps replace chemotherapy as the standard treatment for patients with progressive malignant gastrinoma, especially in those with slow-growing tumors. <ref name="pmid11900219">{{cite journal| author=Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A et al.| title=Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. | journal=Cancer | year= 2002 | volume= 94 | issue= 2 | pages= 331-43 | pmid=11900219 | doi=10.1002/cncr.10195 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11900219 }} </ref> | |||
==References== | ==References== |
Revision as of 23:05, 17 July 2017
Zollinger-Ellison syndrome Microchapters |
Differentiating Zollinger-Ellison syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Zollinger-Ellison syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Zollinger-Ellison syndrome medical therapy |
Risk calculators and risk factors for Zollinger-Ellison syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Pharmacologic medical therapies for Zollinger-Ellison syndrome include proton pump inhibitors, H2-receptor antagonists, chemotherapy, and hormonal therapy.
Medical Therapy
Medical therapy for Zollinger-Ellison syndrome may includes the following:[1]
- Omeprazole 60 mg per day
- Esomeprazole 120 mg per day
- Lansoprazole 45 mg per day [2]
- Rabeprazole] 60 mg per day
- Pantoprazole 120 mg per day [3]
- Used for tumors that can not be surgically resected
- Streptozotocin
- 5-fluorouracil
- Doxorubicin
- Octreotide can be used to slow down acid secretion. Somatostatin analogue octreotide is effective in controlling systemic effects related to multiple liver metastases from a gastrinoma. [4]
- Octreotide is a safe and effective adjunct to surgical strategies for the management of GEP neoplasia in hypergastrinemic MEN-1 patients. [5]
- Octreotide is an effective antitumor treatment in patients with progressive malignant gastrinoma. Octreotide treatment helps replace chemotherapy as the standard treatment for patients with progressive malignant gastrinoma, especially in those with slow-growing tumors. [6]
References
- ↑ Zollinger-Ellison syndrome 2015.https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome
- ↑ Hirschowitz BI, Simmons J, Mohnen J (2005). "Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study". Clin Gastroenterol Hepatol. 3 (1): 39–48. PMID 15645403.
- ↑ Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W; et al. (2006). "Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions". Aliment Pharmacol Ther. 23 (3): 437–44. doi:10.1111/j.1365-2036.2006.02762.x. PMID 16423003.
- ↑ Saijo F, Naito H, Funayama Y, Fukushima K, Shibata C, Hashimoto A; et al. (2003). "Octreotide in control of multiple liver metastases from gastrinoma". J Gastroenterol. 38 (9): 905–8. doi:10.1007/s00535-002-1170-8. PMID 14564638.
- ↑ Burgess JR, Greenaway TM, Parameswaran V, Shepherd JJ (1999). "Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis". Cancer. 86 (10): 2154–9. PMID 10570446.
- ↑ Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A; et al. (2002). "Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma". Cancer. 94 (2): 331–43. doi:10.1002/cncr.10195. PMID 11900219.